Epigenetic age and prognosis in blood cancers
Part of Blood & lymphatic, Cancer, Heart & circulation clinical trials.
This study looks at how 'epigenetic age' (a measure of certain changes in your DNA) relates to the way blood cancers called myeloproliferative neoplasms (MPNs) develop and progress. It may help doctors better understand and predict the course of these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with polycythemia vera, essential thrombocythemia, or primary myelofibrosis.
- A DNA sample from your white blood cells was taken at the time of diagnosis, before any treatment that could affect DNA (like chemotherapy or immunosuppressants).
- You have not been treated with drugs that change DNA methylation (such as cytoreductive therapy, chemotherapy, or immunosuppressants) before the DNA sample was taken.
- You have been followed by your doctor for at least 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at the genetic changes that happen when a myeloproliferative neoplasm (a type of blood cancer) turns into acute myeloid leukemia. It aims to find new treatments that target these specific changes.
This study looks at whether a simple blood test can give the same information as a bone marrow biopsy for people with myeloproliferative neoplasms (MPNs), which are blood cancers that cause the bone marrow to make too many cells. If successful, it could mean less invasive testing for patients.
This study looks at young people (children, teens, and adults under 30) who have a type of blood cancer called myeloproliferative neoplasm (MPN). It aims to better understand the disease and its complications over time, with the goal of improving care.
This study looks at certain markers in the blood to see if they can predict blood clots in people with myeloproliferative neoplasms (MPN) like polycythemia vera, essential thrombocythemia, or pre-myelofibrosis. It is only for people who have a specific JAK2 mutation and are at high risk for clots, and who are already enrolled in another trial and a biobank.
This study explores whether certain inherited gene changes make people more likely to develop myeloproliferative neoplasms (MPNs). It is looking at patients who were diagnosed at a young age or have a family history of blood cancers, to better understand the genetic causes of these conditions.
This study looks for inherited gene changes in people with myeloproliferative neoplasms (MPNs) who have a family history of similar blood disorders. If you qualify, it may help explain why some families have higher risk and could guide future screening.
Hear when a new Myeloproliferative Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.